Cyclin D1

Cyclin D1
Name	Cyclin D1
Gene	CCND1
Locus	11q13
Protein length	295 aa (canonical)
Molecular weight	~34 kDa

Cyclin D1 is a regulatory protein encoded by the CCND1 gene located at 11q13 that coordinates cell cycle progression in response to mitogenic signals. First characterized in studies employing biochemical fractionation in mammalian systems and molecular cloning in laboratories associated with Howard Hughes Medical Institute, Cold Spring Harbor Laboratory, and National Institutes of Health, it links extracellular cues to intracellular machinery controlling G1 to S phase transition. Cyclin D1 has been extensively studied across models from Xenopus laevis and Drosophila melanogaster to human cancer cell lines derived at institutions such as Johns Hopkins University and Memorial Sloan Kettering Cancer Center.

Structure and isoforms

Cyclin D1 is a member of the D-type cyclin family encoded by CCND1 and contains a characteristic cyclin box that mediates binding to cyclin-dependent kinases; structural characterization employed techniques developed at Max Planck Society and European Molecular Biology Laboratory. Alternative splicing of CCND1 produces isoforms including the canonical form and the D1b variant first described in sequencing projects at Sanger Institute and NHGRI; these isoforms differ in C-terminal sequences affecting subcellular localization studied using methods from Stanford University and University of California, San Francisco. Phosphorylation at conserved residues such as Thr286 influences nuclear export and proteasomal degradation through pathways elucidated in collaborations between MIT and Harvard Medical School, while crystal structures of cyclin–CDK complexes determined at EMBL-EBI and Rutherford Appleton Laboratory revealed the molecular interface for regulatory interactions.

Regulation and expression

Expression of CCND1 is regulated transcriptionally by transcription factors including members characterized at Yale University and Columbia University such as those responsive to mitogens like growth factors studied at Roche and Pfizer research centers. Signalling cascades from receptors exemplified by Epidermal Growth Factor Receptor and pathways dissected in reports from University of Cambridge and University College London modulate CCND1 promoter activity; downstream effectors include kinases first identified at MRC Laboratory of Molecular Biology and Cold Spring Harbor Laboratory. Post-translational control involves ubiquitination by E3 ligases investigated at Fred Hutchinson Cancer Center and SUMOylation processes characterized in labs at ETH Zurich. MicroRNA regulation was revealed through consortium efforts including The Broad Institute and Wellcome Trust Sanger Institute; epigenetic modulation implicates chromatin remodelers from The Rockefeller University and histone modification studies at Max Planck Institute for Biophysical Chemistry.

Function in cell cycle and proliferation

Cyclin D1 binds and activates cyclin-dependent kinases CDK4 and CDK6, an interaction framework mapped using structural biology at Brookhaven National Laboratory and biochemical assays developed at University of Chicago. The active cyclin D1–CDK4/6 complexes phosphorylate retinoblastoma protein (pRb), a tumor suppressor whose genetics were elucidated at Institute of Cancer Research and Memorial Sloan Kettering Cancer Center, leading to E2F family transcription factor release discovered by teams at University of California, Berkeley and Cold Spring Harbor Laboratory. This cascade promotes gene expression programs required for S-phase entry; the role of cyclin D1 in lineage-specific proliferation was studied in developmental contexts at University of Oxford and University of Pennsylvania. Cyclin D1 also modulates mitochondrial function and metabolic adaptation in work from University of Michigan and University of Toronto.

Interaction partners and signalling pathways

Beyond CDK4/6, cyclin D1 interacts with numerous partners identified via proteomics at European Bioinformatics Institute and mass spectrometry platforms at National Institute of Standards and Technology. Partners include transcriptional regulators and co-repressors characterized at Yale University and Columbia University, chromatin modifiers studied at Harvard Medical School, and cell cycle checkpoints elucidated at MIT and Stanford University. Cyclin D1 is integrated into signalling networks downstream of receptors like HER2 and PDGFR whose clinical relevance was advanced at Johns Hopkins University and MD Anderson Cancer Center, and it connects to MAPK and PI3K–AKT pathways dissected at UCSF and Cold Spring Harbor Laboratory. Cross-talk with ubiquitin–proteasome components identified at Fred Hutchinson Cancer Center and SUMO pathway enzymes from ETH Zurich modulates its stability.

Role in cancer and disease

Amplification, overexpression, and oncogenic splice variants of CCND1 were first observed in tumor profiling efforts at The Cancer Genome Atlas and International Cancer Genome Consortium; such alterations are frequent in cancers of the breast, head and neck, esophagus, and hematological malignancies investigated at MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Royal Marsden Hospital. CCND1 dysregulation collaborates with mutations in genes like TP53, ERBB2, and PIK3CA whose clinical sequencing was advanced by Sanger Institute and Broad Institute consortia. Germline variants and somatic rearrangements implicating 11q13 have been reported in epidemiological studies from National Cancer Institute and European Society for Medical Oncology. Cyclin D1 also contributes to fibrotic and neurodegenerative contexts explored at Karolinska Institutet and Mayo Clinic.

Diagnostic and therapeutic relevance

Cyclin D1 overexpression serves as a diagnostic marker in pathology workflows at Royal College of Pathologists and panels used in clinical laboratories affiliated with NHS and Mayo Clinic; immunohistochemistry assays standardized by consensus groups at College of American Pathologists detect CCND1 protein levels. Therapeutically, CDK4/6 inhibitors developed by pharmaceutical programs at AstraZeneca, Pfizer, and Novartis (e.g., palbociclib, ribociclib, abemaciclib) target cyclin D1-driven proliferation and are used in breast cancer regimens studied in clinical trials coordinated by NCI and European Medicines Agency. Resistance mechanisms involving PI3K pathway activation and RB loss were characterized in translational studies at Dana-Farber Cancer Institute and Vanderbilt University Medical Center, prompting combination strategies assessed in trials run by SWOG and EORTC.

Category:Cell cycle proteins